Cancer treatments

Compugen to Present Data from Ongoing COM701 Phase 1 Clinical Trial at SITC 2019

Retrieved on: 
Wednesday, October 2, 2019
Medicine, Clinical medicine, Cancer treatments, Bristol-Myers Squibb, Antineoplastic drugs, Breakthrough therapy, Monoclonal antibodies, Nivolumab, Combination therapy, Mapatumumab

COM701 monotherapy dose escalation data in a poster titled "Phase 1 study of the safety, tolerability and preliminary anti-tumor activity of COM701 monotherapy in patients with advanced solid tumors" (Poster no.

Key Points: 
  • COM701 monotherapy dose escalation data in a poster titled "Phase 1 study of the safety, tolerability and preliminary anti-tumor activity of COM701 monotherapy in patients with advanced solid tumors" (Poster no.
  • Update on COM701 combination study with Opdivo in a trial-in-progress poster titled "Phase 1 study of COM701 monotherapy and in combination with nivolumab in patients with advanced solid tumors" (Poster no.
  • P422) will be presented on Saturday, November 9, 2019 from 7:00 am until 8:30 pm ET.
  • The Company will hold a conference call on Monday, November 11, 2019, at 8:30 am ET to review its third quarter 2019 results and SITC poster presentations.

Iovance Biotherapeutics Announces Four Abstracts to be Presented at the Upcoming 2019 SITC Annual Meeting

Retrieved on: 
Wednesday, October 2, 2019
Cancer treatments, Virotherapy, Immunotherapy

One of the abstracts is a late-breaking submission and presentation details will be made available to the public on November 1, 2019.

Key Points: 
  • One of the abstracts is a late-breaking submission and presentation details will be made available to the public on November 1, 2019.
  • Details on the three posters that will be presented as part of the regular submissions are below.
  • Iovance Biotherapeutics intends to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers.
  • Certain matters discussed in this press release are forward-looking statements of Iovance Biotherapeutics, Inc. (hereinafter referred to as the Company, we, us, or our).

Unum Therapeutics Announces Data Presentation at the Upcoming Society for Immunotherapy of Cancer (SITC) Meeting

Retrieved on: 
Wednesday, October 2, 2019
Medicine, Clinical medicine, Medical specialties, Cancer treatments, Virotherapy, Society for Immunotherapy of Cancer, Cancer immunotherapy, SITC, GOT2, Immunotherapy

CAMBRIDGE, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today announced acceptance of a presentation at the 34th annual meeting of the Society for Immunotherapy of Cancer (SITC) being held November 610, 2019 in National Harbor, Maryland.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today announced acceptance of a presentation at the 34th annual meeting of the Society for Immunotherapy of Cancer (SITC) being held November 610, 2019 in National Harbor, Maryland.
  • Our BOXR platform aims to discover novel transgenes co-expressed with chimeric-targeting receptors to improve T cell functionality in the solid tumor microenvironment, said Seth Ettenberg, Ph.D., Chief Scientific Officer of Unum.
  • At this years SITC meeting, we are pleased to present preclinical data from BOXR1030, our first product candidate from this platform, and the role of the addition of the GOT2 transgene to the BOXR1030 construct that was discovered as part of this effort.
  • Follow Unum Therapeutics on social media: @UnumRx , and LinkedIn .

Fennec to Present at the 2019 Cantor Global Healthcare Conference on October 4, 2019

Retrieved on: 
Wednesday, October 2, 2019
Chemistry, Physical sciences, Natural sciences, Cancer treatments, Occupational safety and health, RTT, Ammine complexes, Oncology, Ototoxicity, Chemotherapy, Cisplatin, Platinum

A live audio webcast of the presentation will be available on the investor relations section of Fennecs website at http://investors.fennecpharma.com/events-and-presentations/events .

Key Points: 
  • A live audio webcast of the presentation will be available on the investor relations section of Fennecs website at http://investors.fennecpharma.com/events-and-presentations/events .
  • A replay of the presentation will also be available and archived for 90 days.
  • Cisplatin and other platinum compounds are essential chemotherapeutic components for many pediatric malignancies.
  • Unfortunately, platinum-based therapies cause ototoxicity in many patients, and are particularly harmful to the survivors of pediatric cancer.

BerGenBio to Present Clinical Data From Phase II Trial With Selective AXL Inhibitor at 34th Annual SITC Meeting

Retrieved on: 
Wednesday, October 2, 2019
Cancer treatments, Clinical medicine, Medicine, Antineoplastic drugs, Tyrosine kinase receptors, Merck, Lung cancer, AXL receptor tyrosine kinase, Protein kinase inhibitors, Pembrolizumab, Bemcentinib, Non-small-cell lung carcinoma

The presentation will provide updates on its phase II study of bemcentinib (BGB324) in combination with pembrolizumab in patients with advanced NSCLC.

Key Points: 
  • The presentation will provide updates on its phase II study of bemcentinib (BGB324) in combination with pembrolizumab in patients with advanced NSCLC.
  • Title:A phase II study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC: Updated analysis.
  • Bemcentinib (formerly known as BGB324), is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme.
  • The company's proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad phase II oncology clinical development programme focused on combination and single agent therapy in lung cancer and leukaemia.

BerGenBio to Present Clinical Data From Phase II Trial With Selective AXL Inhibitor at 34th Annual SITC Meeting

Retrieved on: 
Wednesday, October 2, 2019
Cancer treatments, Clinical medicine, Medicine, Antineoplastic drugs, Tyrosine kinase receptors, Merck, Lung cancer, AXL receptor tyrosine kinase, Protein kinase inhibitors, Pembrolizumab, Bemcentinib, Non-small-cell lung carcinoma

The presentation will provide updates on its phase II study of bemcentinib (BGB324) in combination with pembrolizumab in patients with advanced NSCLC.

Key Points: 
  • The presentation will provide updates on its phase II study of bemcentinib (BGB324) in combination with pembrolizumab in patients with advanced NSCLC.
  • Title:A phase II study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC: Updated analysis.
  • Bemcentinib (formerly known as BGB324), is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme.
  • The company's proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad phase II oncology clinical development programme focused on combination and single agent therapy in lung cancer and leukaemia.

Celyad Announces October and November 2019 Investor Conference Schedule

Retrieved on: 
Wednesday, October 2, 2019
Medicine, Clinical medicine, Cancer treatments, Health, Chimeric antigen receptor T cell, Immune system, Lymphoma, Colorectal cancer

Celyads CAR-T cell platform has the potential to treat a broad range of solid and hematologic tumors.

Key Points: 
  • Celyads CAR-T cell platform has the potential to treat a broad range of solid and hematologic tumors.
  • Celyad is also developing CYAD-101, an investigational, non-gene edited, allogeneic (donor derived) NKG2D-based CAR-T therapy, which is currently being evaluated in a Phase 1 trial for the treatment of patients with metastatic colorectal cancer.
  • Celyad was founded in 2007 and is based in Mont-Saint-Guibert, Belgium, and New York, NY.
  • There is limited data concerning safety and clinical activity following treatment with the CYAD-01, CYAD-101 and CYAD-02 drug product candidates.

CAR-T Therapies Market (2nd Edition), 2019-2030

Retrieved on: 
Tuesday, October 1, 2019
Medicine, Clinical medicine, Health, Cancer treatments, Virotherapy, Chimeric antigen receptor T cell, Gene therapy, Immune system, Lymphoma, Immunotherapy, Cancer immunotherapy, Therapy

Further, it includes a discussion on the advent and historical evolution of cancer immunotherapy, general manufacturing procedure of CAR-T cell therapies, factors supporting the growing popularity of CAR-T cell therapies and the challenges associated with such therapies.

Key Points: 
  • Further, it includes a discussion on the advent and historical evolution of cancer immunotherapy, general manufacturing procedure of CAR-T cell therapies, factors supporting the growing popularity of CAR-T cell therapies and the challenges associated with such therapies.
  • Chapter 4 provides insights on the popularity of CAR-T cell therapies on the social media platform, Twitter.
  • In addition, we have provided a detailed list of factors that have influenced the growth of CAR-T therapies market in China.
  • Chapter 10 provides a list of technology platforms that are either available in the market or are being designed for the development of CAR-T cell therapies.

Trovagene Presents Overview of Phase 1b/2 Trial of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer (mCRC) at ESMO

Retrieved on: 
Tuesday, October 1, 2019
RTT, Cancer, Clinical medicine, Infectious causes of cancer, Medicine, Colorectal cancer, NCI-designated Cancer Center, Cancer treatments, Angiogenesis inhibitors, Sirtex

"As of September 1, 2019, four patients have been treated and one has successfully completed their first cycle of treatment.

Key Points: 
  • "As of September 1, 2019, four patients have been treated and one has successfully completed their first cycle of treatment.
  • Colorectal cancer (CRC) is the second leading cause of cancer mortality in the U.S.
  • Despite significant progress in the treatment of mCRC, the majority of patients with metastatic disease succumb to the disease.
  • The trial is being conducted at two prestigious cancer centers: USC Norris Comprehensive Cancer Center and The Mayo Clinic Arizona.

Ziopharm Oncology Announces FDA Clearance of IND for Rapid Personalized Manufacture of CD19-specific CAR-T

Retrieved on: 
Tuesday, October 1, 2019
Medicine, Medical specialties, Clinical medicine, Transplantation medicine, Cancer treatments, Virotherapy, RTT, Hematopoietic stem cell transplantation, Allotransplantation, Leukemia, CD19, Immunotherapy

This trial expands the range of patients with CD19-expressing malignancies that can be treated using the RPM technology, said Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm.

Key Points: 
  • This trial expands the range of patients with CD19-expressing malignancies that can be treated using the RPM technology, said Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm.
  • Existing commercial T-cell products using viral-based manufacturing are costly, time consuming to make and complex to deliver.
  • We are now positioned to not only address those issues, but also to treat a patient group that remains underserved by existing therapies.
  • Treatment of leukemic relapse after allogeneic stem cell transplantation with cytotoreductive chemotherapy and/or immunotherapy or second transplants.